Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 4
2022 7
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy.
Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, Eguren-Santamaria I, Berraondo P, Schalper KA, de Andrea CE, Sanmamed MF, Melero I. Teijeira A, et al. Among authors: olivera i. Clin Cancer Res. 2021 May 1;27(9):2383-2393. doi: 10.1158/1078-0432.CCR-20-1319. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376096 Review.
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, Olivera I, Cañamero M, Alvarez M, Ochoa MC, Rouzaut A, Rodriguez-Ruiz ME, Sanmamed MF, Klein C, Umaña P, Ponz M, Bacac M, Melero I. Teijeira A, et al. Among authors: olivera i. Theranostics. 2022 Jan 1;12(3):1373-1387. doi: 10.7150/thno.63359. eCollection 2022. Theranostics. 2022. PMID: 35154495 Free PMC article.
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy.
Olivera I, Bolaños E, Gonzalez-Gomariz J, Hervas-Stubbs S, Mariño KV, Luri-Rey C, Etxeberria I, Cirella A, Egea J, Glez-Vaz J, Garasa S, Alvarez M, Eguren-Santamaria I, Guedan S, Sanmamed MF, Berraondo P, Rabinovich GA, Teijeira A, Melero I. Olivera I, et al. Cell Rep Med. 2023 Mar 17;4(3):100978. doi: 10.1016/j.xcrm.2023.100978. Online ahead of print. Cell Rep Med. 2023. PMID: 36933554 Free PMC article.
Novel strategies exploiting interleukin-12 in cancer immunotherapy.
Cirella A, Luri-Rey C, Di Trani CA, Teijeira A, Olivera I, Bolaños E, Castañón E, Palencia B, Brocco D, Fernández-Sendin M, Aranda F, Berraondo P, Melero I. Cirella A, et al. Among authors: olivera i. Pharmacol Ther. 2022 Nov;239:108189. doi: 10.1016/j.pharmthera.2022.108189. Epub 2022 Apr 14. Pharmacol Ther. 2022. PMID: 35430292 Review.
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma.
Ochoa MC, Sanchez-Gregorio S, de Andrea CE, Garasa S, Alvarez M, Olivera I, Glez-Vaz J, Luri-Rey C, Etxeberria I, Cirella A, Azpilikueta A, Berraondo P, Argemi J, Sangro B, Teijeira A, Melero I. Ochoa MC, et al. Among authors: olivera i. Cell Rep Med. 2023 Apr 18;4(4):101009. doi: 10.1016/j.xcrm.2023.101009. Epub 2023 Apr 10. Cell Rep Med. 2023. PMID: 37040772 Free PMC article.
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.
Glez-Vaz J, Azpilikueta A, Ochoa MC, Olivera I, Gomis G, Cirella A, Luri-Rey C, Álvarez M, Pérez-Gracia JL, Ciordia S, Eguren-Santamaria I, Alexandru R, Berraondo P, de Andrea C, Teijeira Á, Corrales F, Zapata JM, Melero I. Glez-Vaz J, et al. Among authors: olivera i. Sci Adv. 2023 Aug 18;9(33):eadf6692. doi: 10.1126/sciadv.adf6692. Epub 2023 Aug 18. Sci Adv. 2023. PMID: 37595047 Free article.
Interleukin-18 in cancer immunology and immunotherapy.
Cirella A, Olivera I, Luri-Rey C, Bolaños E, Berraondo P, Melero I. Cirella A, et al. Among authors: olivera i. Expert Opin Ther Targets. 2023 Jul-Dec;27(11):1035-1042. doi: 10.1080/14728222.2023.2287574. Epub 2023 Dec 7. Expert Opin Ther Targets. 2023. PMID: 37993172
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists.
Cirella A, Bolaños E, Luri-Rey C, Di Trani CA, Olivera I, Gomis G, Glez-Vaz J, Pinci B, Garasa S, Sánchez-Gregorio S, Azpilikueta A, Eguren-Santamaria I, Valencia K, Palencia B, Alvarez M, Ochoa MC, Teijeira Á, Berraondo P, Melero I. Cirella A, et al. Among authors: olivera i. Mol Ther Nucleic Acids. 2023 Jul 28;33:668-682. doi: 10.1016/j.omtn.2023.07.026. eCollection 2023 Sep 12. Mol Ther Nucleic Acids. 2023. PMID: 37650116 Free PMC article.
Advances in mRNA-based drug discovery in cancer immunotherapy.
Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P. Di Trani CA, et al. Among authors: olivera i. Expert Opin Drug Discov. 2022 Jan;17(1):41-53. doi: 10.1080/17460441.2021.1978972. Epub 2021 Sep 20. Expert Opin Drug Discov. 2022. PMID: 34496689 Review.
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic.
Alvarez M, Molina C, Garasa S, Ochoa MC, Rodriguez-Ruiz ME, Gomis G, Cirella A, Olivera I, Glez-Vaz J, Gonzalez-Gomariz J, Luri-Rey C, Azpilikueta A, Bolaños E, Teijeira A, Berraondo P, Quintero M, Melero I. Alvarez M, et al. Among authors: olivera i. Oncoimmunology. 2023 Apr 5;12(1):2197370. doi: 10.1080/2162402X.2023.2197370. eCollection 2023. Oncoimmunology. 2023. PMID: 37035637 Free PMC article.
23 results